BiotechTube
Cerus

Cerus

CERS
Concord, United States· Est. 1991

Cerus is a public company focused exclusively on blood safety, aiming to become the preeminent global blood products company. Its flagship INTERCEPT Blood System for platelets and plasma is the only pathogen reduction system with both FDA approval and a CE mark for these components. With a commercial footprint and a late-stage pipeline for red blood cells, Cerus is positioned to address critical safety gaps in the global blood transfusion market.

cerus.com

CERS · Stock Price

USD 1.77+0.34 (+23.78%)
Market Cap: $354.6M

Historical price data

AI Company Overview

Cerus is a public company focused exclusively on blood safety, aiming to become the preeminent global blood products company. Its flagship INTERCEPT Blood System for platelets and plasma is the only pathogen reduction system with both FDA approval and a CE mark for these components. With a commercial footprint and a late-stage pipeline for red blood cells, Cerus is positioned to address critical safety gaps in the global blood transfusion market.

HematologyTransfusion MedicineInfectious Disease

Technology Platform

The INTERCEPT Blood System is a pathogen reduction technology platform that uses synthetic psoralen compounds and UVA light to inactivate a broad spectrum of viruses, bacteria, parasites, and white blood cells in blood components.

Pipeline

11
11 drugs in pipeline2 in Phase 3
DrugIndicationStageWatch
Traditional Cryoprecipitate + Pathogen-Reduced Cryoprecipita...HypofibrinogenemiaApproved
Pathogen-Reduced Plasma + Crystalloid SolutionsBurnsApproved
S-303 Treated Red Blood Cells (RBCs) + Conventional, untreat...Thalassemia MajorPhase 3
S-303 Red Blood Cells (RBCs) - Test + Conventional, untreate...Focus:Use of S303 RBCs in Patients With Acute AnemiaPhase 3
Autologous apheresis Platelet Components, prepared with the ...HealthyPhase 2

Opportunities

The primary growth opportunities include securing FDA approval and commercializing the INTERCEPT system for red blood cells (the largest blood component market) and expanding adoption of its approved platelet and plasma systems through strategic agreements with large blood center networks in the US and internationally.

Risk Factors

Key risks include slower-than-expected commercial adoption due to cost and workflow changes, failure of the red blood cell program in late-stage trials or regulatory review, increased competition from alternative pathogen reduction technologies, and challenges in securing adequate reimbursement from payers.

Competitive Landscape

Cerus's main competitors are Terumo BCT (Mirasol) and Macopharma (Theraflex), which offer alternative pathogen reduction systems primarily in international markets. Cerus differentiates itself by holding the only FDA approval for pathogen reduction of both platelets and plasma in the US, giving it a significant first-mover advantage in the largest blood market.